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Abstract 
Background: To evaluate the association between the timing of best tumor shrinkage (bTS) and 
metastatic renal cell carcinoma (mRCC) patient survival after 1st-line tyrosine kinase inhibitor (TKI) 
therapy. 
Methods: The tumors of 91 patients with mRCC showed a response to TKIs. None of the patients had 
received prior cytokine therapy. The magnitude of bTS was categorized according to the Response 
Evaluation Criteria in Solid Tumors v. 1.1. The patients were divided into two subgroups according to 
the timing of bTS: early responders (≤3 months) and late responders (>3 months). Overall survival 
(OS) and progression-free survival (PFS) after 1st-line TKI therapy were evaluated, and factors 
predicting survival were examined. 
Results: Sunitinib, sorafenib, and pazopanib were used in 62, 25, and 4 responders, respectively. In 
total, 52 (57.1%) and 39 (42.9%) patients were early and late responders, respectively. Early 
responders had significantly lower PFS compared to late responders (median survival: 11.4 vs. 19.1 
months, log-rank test: p = 0.0263), although there were no significant differences in the OS of early 
and late responders (27.0 vs. 30.1 months, p = 0.306). Multivariate analyses revealed that the timing 
of bTS was an independent predictor of PFS and OS (PFS: hazard ratio 4.09, p < 0.0001; OS: hazard 
ratio 2.32, p = 0.0107). 
Conclusion: The timing of bTS was an independent predictor of survival in patients with mRCC who 
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received 1st-line TKIs. 
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Introduction 
 The standard treatment strategy for metastatic renal cell carcinoma (mRCC) consists of molecular-
targeted agents, and the prognosis of patients has improved, compared to that observed in the era of 
cytokine therapy [1]. Among molecular-targeted agents, tyrosine kinase inhibitors (TKIs), which are 
multi-targeted inhibitors of receptors for vascular endothelial growth factors, have powerful antitumor 
activities against mRCC, as demonstrated in previous randomized trials [2-4].  
 As the response and survival rates have improved since the introduction of targeted agents, the 
prognostic or predictive indicators of outcomes have been investigated. In this context, the objective 
response, i.e., tumor shrinkage (TS), based on the standard Response Evaluation Criteria in Solid 
Tumors (RECIST) [5], is a useful marker for predicting the outcomes. The best TS (bTS), which is the 
magnitude of maximum TS [6,7], or early TS, which is the magnitude of TS at a single cut-off time, 
for example 3 months after therapy initiation [8,9], is an independent predictor of survival after 
targeted agent therapy. However, to the best of our knowledge, studies that investigated the influence 
of timing of bTS on survival are limited. Moreover, in the previous studies [6-10], the cohorts consisted 
of patients who received prior cytokine therapy; as the current treatment strategy for mRCC includes 
the use of molecular-targeted agents without previous cytokine therapy [2,11,12], data are needed from 
patients who have not received previous cytokine therapy. 
Therefore, in this study, we evaluated the influence of timing of bTS on patient survival among 
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patients with mRCC who received 1st-line TKI therapy without prior cytokine therapy. 
 
Patients and methods 
Patients and study design  
 The Internal Ethics Review Board of Tokyo Women’s Medical University approved this retrospective 
study (ID: 3871), which was performed in accordance with the principals outlined in the Declaration 
of Helsinki.  
 In our department, a total of 242 patients received 1st-line TKIs (115 who received sunitinib; 120, 
sorafenib; and 7, pazopanib) between January 2008 and March 2015. Of these 242 patients, 40 patients 
who had received prior cytokine therapy, 21 patients who had received TKIs for less than 4 weeks, 23 
patients who had received hemodialysis or kidney transplantation, and 45 patients whose detailed 
clinical or imaging data were missing were excluded. Furthermore, we excluded 22 patients because 
no tumor response was observed after therapy initiation. The remaining 91 patients (62 who received 
sunitinib; 25, sorafenib; and 4, pazopanib) were enrolled. These patients were divided into two 
subgroups according to the timing of bTS. Patients were categorized as early responders when the 
maximum TS was obtained within 3 months after therapy initiation and the tumors did not shrink any 
more after that. Similarly, late responders were defined as those who showed maximum TS after 3 
months since therapy initiation (Figure 1). Clinical and laboratory data were obtained from the 
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electronic database and patient medical records.  
 
Imaging methods and imaging evaluation  
Baseline imaging examinations, including plain or contrast-enhanced computed tomography or 
magnetic resonance imaging of the chest, abdomen, and pelvis, was performed within 28 days before 
the start of a new therapy course. Regular scans were also performed every 8-12 weeks of therapy, 
according to the patients’ condition. 
The target lesions were selected on the basis of the baseline imaging results, and evaluated according 
to RECIST v. 1.1 [5]. The bTS was defined as the time point at which maximum TS was observed 
(percentage change in the sum diameter of all the target lesions). Sclerotic osseous lesions were 
excluded. Two investigators (H.I. and T.Y.), who were blinded to all other clinical parameters and the 
patient outcomes, performed all image analyses. 
 In this study, response duration was defined as the time between initial response with > 0% tumor 
shrinkage and disease progression.   
 
TKI regimens 
 In this study, none of the patients had received prior cytokine therapy. About the strategy of targeted 
therapy used in this study, the first-choice agent was sorafenib until December 2008 when sunitinib 
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could not be used in our department because of it had not yet been approved for use. After December 
2008, we used sunitinib as the 1st-line agent.  
In the sunitinib regimen, we treated our patients with mRCC using a 4-week-on/2-week-off schedule 
or a 2-week-on/1-week-off schedule on the basis of the findings in our previous study [13]. Sunitinib 
treatment was initiated at a dosage of 50 mg/day, and was modified according to the following three 
patient factors: (1) age of >65 years, (2) serum creatinine levels of >2 mg/dL, and (3) a body weight 
of <50 kg. If one of these three factors was noted, the initial dose was reduced to 37.5 mg. If two of 
these three factors were observed, the initial dose was reduced to 25 mg. Even if all the three factors 
were observed, we never reduced the initial dose to <25 mg. The dose was subsequently increased by 
12.5 mg until we found the highest dose that these patients could tolerate, although this dose never 
exceeded 50 mg.  
 In the sorafenib regimen, 400 mg sorafenib was administered twice daily, with a continuous dosing 
schedule. When severe adverse events (AEs) developed, the dose was reduced to 400 mg once daily, 
followed by an additional reduction to a single 400 mg dose every alternate day.  
 When patients had a poor performance status or were elderly (>65 years), pazopanib was chosen as 
the 1st-line TKI agent. In the pazopanib regimen, pazopanib was administered orally once daily at a 
dose of 800mg, with continuous dosing. The dose was reduced to 600 mg and then to 400 mg according 
to the severity of the AEs. 
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In all the regimens, the drugs were administered until disease progression was observed or intolerable 
AEs developed.  
 
Statistical analysis  
 Continuous variables were analyzed using the Mann-Whitney U-test, and categorical variables were 
analyzed using the χ2 test. Progression-free survival (PFS) and overall survival (OS) after the 
administration of the 1st-line TKIs were calculated using the Kaplan-Meier method, and compared 
using the log-rank test. PFS was defined as the time of 1st-line TKI initiation to the date of progression 
or death from any cause, whichever came first. OS was defined as the time of 1st-line TKI initiation to 
death from any cause. Univariate and multivariate analyses were used to identify factors that were 
associated with PFS and OS, via Cox proportional hazards regression models. Risk of survival was 
expressed as hazard ratios (HR) and 95% confidence intervals (CIs). All analyses were performed 
using JMP software (version 11; SAS Institute Inc., Cary, NC, USA), and differences were considered 
statistically significant at p-values of <0.05. 
 
Results 
Patient characteristics  
According to the timing of bTS, 52 and 39 patients were early and late responders, respectively. There 
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were no significant differences in the patient baseline characteristics (Table 1). The rate of patients 
with pancreatic metastasis was significant higher among late responders (p = 0.0171). There was no 
significant difference in magnitude of bTS according to categorical classification based on RECIST 
and continuous variable (p > 0.05, both). As expected, time from treatment initiation to bTS was 
significantly earlier in early responders (p < 0.0001), whereas response duration between the initial 
response to disease progression did not significantly differ between early and late responders (p = 
0.716). Moreover, magnitude of tumor shrinkage within first 3 months after treatment initiation (i.e., 
initial evaluation) was significantly greater in early responders according to categorical classification 
based on RECIST and continuous variable (p < 0.05, both). 
The magnitude of bTS of target lesions according to the 1st-line targeted agents is demonstrated by 
using a waterfall plot for individual patients (Figure 2).  
 
Survival according to the timing of bTS   
 During the follow-up period, disease progression and death occurred in 67 and 44 patients, 
respectively. Figure 3 and Figure 4 show the Kaplan-Meier survival curves of PFS and OS after 1st-
line TKI therapy according to the timing of bTS. Early responders had significantly shorter PFS 
compared to late responders (median survival: 11.4 vs. 19.1 months, p = 0.0263), although there was 
no significant difference in OS between early and late responders (27.0 vs. 30.1 months, p = 0.306). 
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Prognostic indicators for patient survival 
 On univariate analysis, the significant predictors of PFS were pathology, prior nephrectomy status, 
number of metastatic organs, baseline volume of metastasis, magnitude of bTS, response duration, and 
timing of bTS (all. p < 0.05), and the Memorial Sloan Kettering Cancer Center (MSKCC) outcome 
classification tended towards significance (p = 0.0543). On multivariate analysis for PFS, the timing 
of bTS was an independent predictor (HR 4.09, p < 0.0001), along with the MSKCC outcome 
classification (p = 0.0365) and response duration (p < 0.0001) (Table 2). On univariate analysis, the 
significant predictors of OS were prior nephrectomy status, MSKCC outcome classification, number 
of metastatic organs, baseline volume of metastasis, and response duration (all, p < 0.05). On 
multivariate analysis for OS, the timing of bTS was an independent predictor (HR 2.32, p = 0.0107), 
along with MSKCC outcome classification (p = 0.0050), number of metastatic organs (p = 0.0214), 
baseline volume of metastasis (p = 0.0035), and response duration (p < 0.0001) (Table 3). 
 
Outcomes after 1st-line TKI failure according to the timing of bTS 
 We evaluated the outcomes of 67 patients who subsequently showed failure to 1st-line TKIs. There 
were no significant differences in the rate of shifting to 2nd-line therapy between early and late 
responders (68.3% vs. 57.7%, respectively; p = 0.438). Among 43 patients who were shifted to 2nd-
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line therapy, of the early responders, 6 received sunitinib, 1 received sorafenib, 17 received axitinib, 
and 4 received everolimus; and of the late responders, 2 received sunitinib, 1 recieved pazopanib, 7 
received axitinib, 2 received temsiroimus, and 3 received everolimus (Table 4). Among the 43 
responders, the Kaplan-Meier survival curves for OS after 2nd-line therapy revealed that there were no 
significant differences between early (n = 28) and late responders (n = 15) (median survival: 13.2 vs. 
19.9 months, p = 0.764) (Figure 5).  
 
Discussion 
The present study revealed that the timing of bTS was an independent predictor of PFS and OS among 
the patients with mRCC who received 1st-line TKIs without prior cytokine therapy. We did not observe 
any significant correlation between the timing of bTS and OS according to the log-rank test. However, 
on multivariate analysis, the timing of bTS was an independent predictive factor of PFS and OS, after 
adjustments of other factors. Moreover, we found no significant differences in the outcomes after 1st-
line TKI failure; the rate of patients who could be shifted to 2nd-line therapy, and the OS after 2nd-line 
therapy did not differ between early and late responders. Hence, the timing of bTS during 1st-line TKI 
therapy was an independent predictor of survival, regardless of the outcomes after 1st-line TKI failure. 
These results indicated that evaluating imaging a second time (or more) can possibly predict patient 
prognosis; therefore, we believe that timing of bTS can be utilized as a new and effective predictive 
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marker in clinical practice because it can be evaluated while TKI treatment is ongoing.  
The molecular-targeted agents such as TKIs, which inactive multiple signal transduction pathways 
that mediate angiogenesis, have been developed for the treatment of mRCC. These new agents 
contributed to improving the prognosis of patients with mRCC, compared to that observed in the 
cytokine era [1]. The magnitude of bTS could predict patient survival in those who received 1st-line 
targeted therapy [6], as well as those who received 2nd-line therapy [7,14]. According to a previous 
study by Grünwald et al. [7], survival was significantly correlated with the depth of remission during 
1st- and 2nd-line therapy. However, in clinical practice, it is difficult to predict when we can observe 
bTS during treatment. Meanwhile, early TS was also identified as an effective predictor of the survival 
of patients with mRCC who received 1st-line targeted therapy [8,9]. Recently, Miyake et al. [9] 
suggested that the magnitude of early TS, identified 3 months after therapy initiation, was an 
independent prognostic indicator of OS among patients with mRCC who received 1st-line sunitinib 
and sorafenib. This method with fixed a time-point can be used to resolve a weak point of the 
magnitude of bTS for predicting survival.  
However, it remains unclear how the timing of bTS influences patient survival after 1st-line TKI 
therapy. Molina et al. [10] previously reported that the timing of bTS significantly influenced PFS (p 
= 0.001) but not OS (p = 0.144) in a large cohort study among patients who received 1st-line sunitinib, 
although the Kaplan-Meier curve seemed to show a tendency towards a significant difference in OS. 
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However, in their study, only the Kaplan-Meier method was performed; multivariate analysis was not 
performed. Moreover, because their cohort consisted of patients who had participated in previous trials, 
the general condition of the enrolled patients might have been better than that of patients usually 
observed in clinical settings. Furthermore, approximately 25% of the patients in the cohort studied by 
Molina et al. [10] were treated with prior cytokine therapy (101/398 responders). Hence, the present 
study demonstrates that the timing of bTS is an independent predictor of PFS and OS of patients with 
mRCC after 1st-line TKIs without prior cytokine therapy in clinical settings. In this study, multivariate 
analysis revealed that the timing of bTS was an independent predictor of OS, although the Kaplan-
Meier method did not show statistical difference. This difference might be caused by a severe 
confounding bias. After adjusting for other factors including prior nephrectomy status, MSKCC 
outcome classification, number of metastatic organs, tumor burden, and response duration [15-19], the 
timing of bTS was shown to be an independent predictive factor. Furthermore, MSKCC outcome 
classification, number of metastatic organs, baseline volume of metastasis, and response duration also 
remained significant predictive indicators. We believe that these results obtained on multivariate 
analysis should be emphasized. 
Our analysis showed that late responders had superior PFS and OS compared to early responders, 
and among all responders, 42.9% were late responders. This rate was similar to that obtained by 
Molina et al. [10] (38.9%, 155/398 sunitinib-responders). This information obtained in the study by 
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Molina et al. [10] and in our study is important because some tumors showed slow tumor shrinkage 
during a relatively long treatment period. Moreover, some late responders (25.6%) had no response at 
initial treatment evaluation (i.e., within the first 3 months after treatment initiation), and had weaker 
tumor shrinkage compared to early responders, as shown in Table 1. In this context, these results 
indicated that even if initial tumor response was poor, some patients subsequently had a higher 
magnitude of tumor shrinkage, that resulting in better prognosis.  
This study has several limitations. First, as this was a retrospective, single-center study with a 
relatively small cohort, our survival analyses may have some bias. Therefore, our results should be 
confirmed in a prospective, multi-institution study with a large cohort. Second, we did not consider 
the withdrawal period and/or dose changes of agents caused by the AEs; the true duration and/or 
density (i.e., relative dose intensity) of treatment were not assessed. In addition, the enrolled patients 
in the present study were administered various kinds of TKIs, and the schedule or density was not 
uniform. Third, the indications for treatment with targeted agents were not determined according to 
strictly established criteria, which may have affected the outcomes of this study. Forth, the present 
study showed that late responders had superior survival rates compared to early responders, in spite 
of the weaker magnitude of initial tumor shrinkage; however, this result seemed to be inconsistent 
with findings from previous studies [8,9]. Seidel et al. [8] and Miyake et al. [9] reported that 
initial/early stronger tumor shrinkage was defined as a predictor of mRCC in patients receiving TKI 
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treatment. However, in their studies, the influence of bTS magnitude was not evaluated. Moreover, 
there were differences in study cohorts and factors evaluated in the multivariate analyses. Thus, these 
differences might explain the discrepancy between their and our results.  
In conclusion, the present study demonstrated that the timing of bTS was an independent predictive 
factor of PFS and OS among patients with mRCC who showed a response to 1st-line TKIs. Late 
responders had superior survival after 1st-line TKI therapy compared to early responders, regardless 
of the outcomes after 1st-line failure. This new marker may enable effective prediction of patient 
survival during treatment.   
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Figure legends 
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Figure 1: Patient selection 
SU, sunitinib; SO, sorafenib; PA, pazopanib; CK, cytokine; HD, hemodialysis; KTx, kidney 
transplantation; TKI, tyrosine kinase inhibitor; TS, tumor shrinkage  
 
Figure 2: Waterfall plot 
Waterfall plot showing the magnitude of best tumor shrinkage according to the 1st-line TKIs used in 
each patient, with comparisons of SU (blue bar, n = 62), SO (red, n = 25), and PA (green, n = 4). TKI, 
tyrosine kinase inhibitor; SU, sunitinib; SO, sorafenib; PA, pazopanib 
 
Figure 3: Progression-free survival according to response to 1st-line tyrosine kinase inhibitor therapy  
The survival rate was calculated by the Kaplan-Meier method, and statistical significance was 
compared using the log-rank test (p = 0.0263). 
 
Figure 4: Overall survival according to response to 1st-line tyrosine kinase inhibitor therapy 
The survival rate was calculated by the Kaplan-Meier method, and statistical significance was 
compared using the log-rank test (p = 0.306). 
 
Figure 5: Overall survival after 2nd-line targeted therapy according to timing of best tumor shrinkage 
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after 1st-line tyrosine kinase inhibitor therapy (n = 43) 
The survival rate was calculated by the Kaplan-Meier method, and statistical significance was 
compared using the log-rank test (p = 0.764). 
 
Table 1: Patient characteristics 
 
Variable Early responders  
(n = 52) 
Late responders 
(n = 39) 
p* 
Mean age, year (median, range) 66.2 (68.0, 29.0 – 87.0) 65.1 (65.0, 41.0 – 77.0) 0.249 
Sex 
 Male 
 Female 
 
40 (76.9%) 
12 (23.1%) 
 
29 (74.4%) 
10 (25.6%) 
0.777 
Pathology 
 CCC 
 Non-CCC 
  CCC with spindle  
  MTSC 
  PRCC type 2 
  Medullary carcinoma  
  Unknown 
 
44 (84.6%) 
8 (15.4%) 
1 (1.92%) 
0 
2 (3.85%) 
1 (1.92%) 
4 (7.69%) 
 
30 (76.9%) 
9 (23.1%) 
4 (10.3%) 
2 (5.13%) 
1 (2.56%) 
0 
2 (5.13%) 
0.352 
Prior nephrectomy 
 With  
  Radical nephrectomy 
  Partial nephrectomy 
 Without 
 
47 (90.4%) 
45 (86.5%) 
2 (3.85%) 
5 (9.62%) 
 
34 (87.2%) 
30 (76.9%) 
4 (10.3%) 
5 (12.8%) 
0.629 
Time from diagnosis to treatment, day 
 ≥ 365 day 
 < 365 day 
 
14 (26.9%) 
38 (73.1%) 
 
14 (35.9%) 
25 (64.1%) 
0.359 
MSKCC outcome classification 
 Favorable 
 Intermediate 
 Poor 
 
8 (15.4%) 
39 (75.0%) 
5 (9.62%) 
 
9 (23.1%) 
27 (69.2%) 
3 (7.69%) 
0.637 
Targeted agent 
 Sunitinib 
 Sorafenib 
 Pazopanib 
 
35 (67.3%) 
15 (28.9%) 
2 (3.85%) 
 
27 (69.2%) 
10 (25.6%) 
2 (5.13%) 
0.915 
Other therapy 
 With 
  Radiation  
  Metastatectomy 
 
8 (15.9%) 
4 (7.69%) 
4 (7.69%) 
 
11 (28.2%) 
7 (17.9%) 
5 (12.8%) 
0.137 
 Without 44 (84.6%) 28 (71.8%) 
Metastatic lesions  
 Solitary 
 Multiple 
 
20 (38.5%) 
32 (61.5%) 
 
16 (41.0%) 
23 (59.0%) 
0.805 
Metastatic organ 
 Lungs 
 Bone 
 Liver 
 Adrenal grands  
 Pancreas  
 Lymph nodes 
 Other 
 
40 (76.9%) 
11 (21.2%) 
7 (13.5%) 
3 (5.77%) 
1 (1.92%) 
17 (32.7%) 
5 (9.62%) 
 
26 (66.7%) 
11 (28.2%) 
4 (10.3%) 
6 (15.4%) 
6 (15.4%) 
11 (28.2%) 
5 (12.8%) 
 
0.278 
0.437 
0.643 
0.128 
0.0171 
0.646 
0.629 
Mean baseline volume of metastasis, cm (median, range) 7.54 (4.70, 1.0 – 42.7) 9.06 (6.10, 1.30 – 31.5) 0.151 
Magnitude of bTS (categorical classification based on RECIST) 
 -100% (CR) 
 - 30% to -100% (PR)  
 0% to -30%  
 
3 (5.77%) 
14 (26.9%) 
35 (67.3%) 
 
3 (7.69%) 
14 (35.9%) 
22 (56.4%) 
0.568 
Magnitude of bTS (continuous variable), % -27.6 (-18.1, -100 - -1.3) -32.2 (-23.0, - 100 - -1.1) 0.365 
Time to bTS, month 2.42 (2.5, 0.53 – 3.71) 8.68 (6.64, 4.27 – 39.4) < 0.0001 
Response duration 
 ≥ 6 months 
 < 6 months 
 
30 (57.7%) 
22 (42.3%) 
 
20 (51.3%) 
19 (48.7%) 
0.543 
Magnitude of tumor shrinkage within first 3 months (categorical classification based 
on RECIST) 
 -100% (CR) 
 - 30% to -100% (PR) 
0% to - 30% 
> 0% 
 
 
3 (5.77%) 
14 (26.9%) 
35 (67.3%) 
0 
 
 
0 
12 (30.8%) 
17 (43.6%) 
10 (25.6%) 
0.0005 
Magnitude of tumor shrinkage within first 3 months (continuous variable) -27.6 (-18.1, -100 − -1.3)  -14.4 (-10.1, -86.5 – 21.9) 0.0096 
Mean follow-up period, months (median, range)  23.3 (19.9, 4.31 – 67.7) 29.0 (21.4, 5.95 – 87.2) 0.106 
*p-value is analyzed between early and late responders. 
 
CCC, clear cell carcinoma; MTSC, mucinous tubular and spindle cell carcinoma; PRCC, papillary 
renal cell carcinoma; MSKCC, Memorial Sloan Kettering Cancer Center; bTS, best tumor shrinkage; 
RECIST, Response Evaluation Criteria in Solid Tumors; CR, complete response; PR, partial 
response; SD, stable disease 
 
Table 2: Univariate and multivariate analyses for progression-free survival 
 
Variable Univariate 
HR (95% CI) 
p Multivariate 
HR (95% CI) 
p 
Age 0.99 (0.96 – 1.02) 0.557 
  
Sex 
 Male 
 Female 
 
Ref. 
1.15 (0.62 – 2.00) 
 
- 
0.641 
  
Pathology 
 CCC 
 Non-CCC/ Unknown 
 
Ref. 
2.17 (1.17 – 3.80) 
 
- 
0.0159 
 
Ref. 
1.09 (0.55 – 2.05) 
 
- 
0.798 
Prior nephrectomy 
 With 
 Without 
 
Ref. 
3.38 (1.52 – 6.76) 
 
- 
0.0042 
 
Ref. 
1.19 (0.49 – 1.83) 
 
- 
0.692 
Time from diagnosis to treatment 
 ≥ 365 day 
 < 365 day 
 
Ref. 
1.55 (0.92 – 2.73) 
 
- 
0.104 
  
MSKCC outcome classification  
 Favorable/ Intermediate  
 Poor 
 
Ref. 
2.59 (0.98 – 5.69) 
 
- 
0.0543 
 
Ref. 
3.12 (1.08 – 7.87) 
 
- 
0.0365 
Targeted agent 
 Sunitinib 
 Sorafenib/ Pazopanib 
 
Ref. 
1.07 (0.64 – 1.75) 
 
- 
0.780 
  
Metastatic lesions 
 Solitary 
 Multiple 
 
Ref. 
2.70 (1.57 – 4.73) 
 
- 
0.0002 
 
Ref. 
1.57 (0.82 – 3.07) 
 
- 
0.176 
Baseline volume of metastasis 1.06 (1.03 – 1.08) 0.0003 1.02 (0.99 – 1.05) 0.219 
Magnitude of bTS 
 -30% to -100% 
 0% to -30%  
 
Ref. 
1.75 (1.05 – 2.99) 
 
- 
0.0304 
 
Ref. 
1.24 (0.69 – 2.27) 
 
- 
0.472 
Response duration 
 ≥ 6 months 
 < 6 months 
 
Ref.  
8.70 (4.76 – 16.3) 
 
- 
< 0.0001 
 
Ref. 
13.8 (6.32 – 31.0) 
 
- 
< 0.0001 
Timing of bTS 
 Early responder  
 
1.75 (1.07 – 2.93) 
 
0.0258 
 
4.09 (2.24 – 7.81) 
 
< 0.0001 
 Late responder Ref. - Ref. - 
 
HR, hazard ratio; CI, confidence intervals; CCC, clear cell carcinoma; ; MSKCC, Memorial Sloan 
Kettering Cancer Center; bTS, best tumor shrinkage; CR, complete response; PR, partial response; SD, 
stable disease 
 
Table 3: Univariate and multivariate analyses for overall survival 
 
Variable Univariate 
HR (95% CI) 
p Multivariate 
HR (95% CI) 
p 
Age 0.99 (0.96 – 1.02) 0.487 
  
Sex 
 Male 
 Female 
 
Ref. 
1.32 (0.63 – 2.55) 
 
- 
0.446 
  
Pathology 
 CCC 
 Non-CCC/ Unknown 
 
Ref. 
1.64 (0.76 – 3.22) 
 
- 
0.196 
  
Prior nephrectomy 
 With 
 Without 
 
Ref. 
5.48 (2.23 – 12.4) 
 
- 
0.0005 
 
Ref. 
1.83 (0.71 – 4.37) 
 
- 
0.200 
Time from diagnosis to treatment 
 ≥ 365 day 
 < 365 day 
 
Ref. 
1.64 (0.85 – 3.42) 
 
- 
0.141 
  
MSKCC outcome classification 
 Favorable/ Intermediate  
 Poor 
 
Ref. 
4.42 (1.47 – 10.8) 
 
- 
0.0109 
 
Ref. 
5.90 (1.81 – 16.5) 
 
- 
0.0050 
Targeted agent 
 Sunitinib 
 Sorafenib/ Pazopanib 
 
Ref. 
1.11 (0.59 – 2.04) 
 
- 
0.733 
  
Metastatic lesions 
 Solitary 
 Multiple 
 
Ref. 
3.55 (1.80 – 7.68) 
 
- 
0.0002 
 
Ref. 
2.51 (1.14 – 5.90) 
 
- 
0.0214 
Baseline volume of metastasis 1.08 (1.05 – 1.11) <0.0001 1.05 (1.02 – 1.09) 0.0035 
Magnitude of bTS 
 -30% to -100% 
 0% to -30%  
 
Ref. 
1.66 (0.88 – 3.30) 
 
- 
0.119 
  
Response duration  
 ≥ 6 months 
 < 6 months 
 
Ref. 
6.05 (3.19 – 11.8) 
 
- 
< 0.0001 
 
Ref. 
6.70 (3.11 – 14.7) 
 
- 
< 0.0001 
Timing of bTS 
 Early responder  
 Late responder 
 
1.37 (0.75 – 2.58) 
Ref. 
 
0.304 
- 
 
2.32 (1.21 – 4.60) 
Ref. 
 
0.0107 
- 
HR, hazard ratio; CI, confidence intervals; CCC, clear cell carcinoma; ; MSKCC, Memorial Sloan 
Kettering Cancer Center; bTS, best tumor shrinkage; CR, complete response; PR, partial response; 
SD, stable disease 
 
Table 4: Comparison of 2nd-line targeted therapy according to timing of tumor shrinkage (24 patients 
without progression disease during 1st-line therapy were excluded). 
 
2nd-line therapy All (n = 67) Early responders 
(n = 41) 
Late responders 
(n = 26) 
p 
2nd-line targeted therapy status 
 With  
 Without 
 
43 (64.2%) 
24 (35.8%) 
 
28 (68.3%) 
13 (31.7%) 
 
15 (57.7%) 
11 (42.3%) 
0.438 
Agents  
 Sunitinib 
 Sorafenib 
 Pazopanib 
 Axitinib 
 Temsirolimus 
 Everolimus 
 
8 (18.6%) 
1 (2.33%) 
1 (2.33%) 
24 (55.8%) 
2 (4.65%) 
7 (16.3%) 
 
6 (21.4%) 
1 (3.57%) 
0  
17 (60.7%) 
0  
4 (14.3%) 
 
2 (13.3%) 
0 
1 (6.67%) 
7 (46.7%) 
2 (13.3%) 
3 (20.0%) 
 
 





